First Vioxx trial begins in US


ANGLETON, Texas (AP) - The first Vioxx-related lawsuit to go to trial opened with the plaintiff's lawyer contending that Merck & Co. traded its mission of treating sickness for relentless marketing and pursuit of profits. 

Attorney Mark Lanier displayed the phrase "Merck-y ethics'' on a large screen Thursday and promised to skewer the judgment of a company he said knew the popular painkiller could be dangerous years before a study showed it could double risk of heart attack or stroke.  

That study prompted Merck to voluntarily remove it from the market last year. 

In a much more subdued presentation, Merck lawyer David Kiernan, who is also a surgeon, urged jurors to keep an open mind as Merck seeks to show the company didn't rush a lucrative drug to market and slip shoddy science past the Food and Drug Administration to pump up profits. 

"That charge could not be more false,'' he said. 

Lanier is representing Carol Ernst, whose husband died in his sleep four years ago of an arrhythmia, or irregular heartbeat. 

Robert Ernst, a personal trainer, had been taking Vioxx for about eight months to ease pain in his hands. 

Lawyers from throughout the country associated with other Vioxx lawsuits packed the courtroom the opening statements before a 12-member jury. 

The trial resumes Monday afternoon with the beginning of testimony. 

Kiernan said Vioxx has been in development since 1991 and cut in half the potentially lethal stomach bleeding that some patients got from traditional pain relievers like aspirin. 

Vioxx was tested in 58 clinical trials involving 10,000 patients before it went on the market, he said, far surpassing FDA testing recommendations. 

Buttressed by photos, graphics and documents shown on a large screen behind him, Lanier targeted former Merck CEO Ray Gilmartin.  

He described Gilmartin as the first non-doctor or non-scientist - "a Harvard-trained businessman'' - to run Merck, starting in 1994. 

Lanier said Gilmartin aimed to turn Merck into "an ATM machine that's spitting out money'' by beefing up sales with glitzy television ads for various drugs - including Vioxx, which came on the market in 1999. 

Vioxx was critical to Merck, Lanier alleged, because patents on other lucrative drugs ran out in 2000 and 2001 and "if Vioxx doesn't fill up the ATM machine for us, we're running dry. It's Vioxx or bust.'' 

He said the company downplayed studies that raised concerns about Vioxx's safety and pushed the painkiller to a growing market of arthritis sufferers and their doctors to keep the bottom line robust. 

"You watch what happens to their studies. It will make you sick,'' Lanier said. 

He said Merck wined and dined Robert Ernst's doctor, Brent Wallace, and targeted him and many other doctors in a plan to push them to prescribe Vioxx. 

He said the company paid doctors to let Merck sales representatives watch them write those prescriptions. 

Kiernan said doctors aren't bought so easily. 

"It doesn't say much about the doctors if they will choose your medicine based on whether you take them to a baseball game,'' he said. 

"They don't, and they won't.'' 

The case in Angleton, a town about 40 miles (64 kilometers) south of Houston, is the first of more than 3,800 state and federal lawsuits pending against New Jersey-based Merck. 

Merck has said claims the company responsibly researched Vioxx's safety in numerous clinical trials before the FDA approved it, and monitored the drug after it went on the market in 1999. 

Merck contends no studies link Vioxx to arrhythmia, and therefore Vioxx couldn't have caused Robert Ernst's death. 

Lanier told jurors he aims to show a heart attack causes arrhythmia, and Ernst's sudden death left no time for any heart damage to show. 

The trial is expected to last five weeks. 

About 20 million people took the antiinflammatory drug prescribed for arthritis and acute pain since it came on the market in 1999. In 2000, a study found that some Vioxx users suffered five times as many heart attacks as users of the older painkiller naproxen, sold under the brand name Aleve. 

In 2002, the FDA added warnings to Vioxx's label.  

Continued research showed Vioxx doubled the risk of heart attack or stroke if taken for 18 months or longer, which prompted Merck to pull the drug. - AP 

Latest business news from AP-Wire 

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 3
   

Did you find this article insightful?

Yes
No

Next In Business News

Malaysia initiates WTO dispute over EU palm oil measures
Goldman Sachs blockbuster profit helps absorb US$3bil Malaysian 1MDB settlement
Oil price gains on stimulus optimism ahead of Biden inauguration
ANALYSIS-Yellen-backed policies set to aid risk assets, raise longer-term worries
Lumentum to buy laser manufacturer Coherent Inc in US$5.7bil deal
Wall St closes higher as Yellen backs more stimulus
Cushioning the impact of MCO 2.0
The perk that fuelled UK Covid housing boom is as good as gone
Hartalega likely to see record 643% surge in earnings
Cagamas kicks off 2021 with bonds, sukuk issuances worth RM710mil

Stories You'll Enjoy